Home › ARCA Biopharma Announces Health Canada Acceptance Of Genetic-AF Clinical Trial Application
 

Keywords :   


ARCA Biopharma Announces Health Canada Acceptance Of Genetic-AF Clinical Trial Application

2014-09-03 11:53:10| drugdiscoveryonline Home Page

ARCA biopharma, Inc. a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, recently announced that the Company’s Clinical Trial Application (CTA) for the GENETIC-AF clinical trial evaluating GencaroTM as a potential treatment for atrial fibrillation (AF) has been accepted by Health Canada

Tags: health canada application trial

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.05Atlantic Tropical Weather Outlook
28.05Low Environmental Impact Recycled Paints Arrive in Indonesia
28.05Eastern North Pacific Tropical Weather Outlook
28.05Ousted WeWork boss drops effort to return
28.05Baldwin Technology unveils new products at drupa
28.05Royal Mail owners to back 5bn takeover offer
28.05Malaysian printers turns to Vetaphone and Nordmeccanica
28.05Katun DPS promotes digital label printing at drupa
More »